Serum chemerin is associated with inflammatory and metabolic parameters—results of a population-based study

Obesity

Volumn 25, Issue 2, 2017, Pages 468-475

  Zylla, Stephanie ^a,b   Pietzner, Maik ^a,b   Kühn, Jens Peter ^a   Völzke, Henry ^a,b,c   Dörr, Marcus ^a,b   Nauck, Matthias ^a,b   Friedrich, Nele ^a,b,d  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^d Research Centre for Prevention and Health   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHEMERIN; FIBRINOGEN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; CHEMERIN PROTEIN, HUMAN; CHEMOKINE; CYTOKINE; LIPID; SIGNAL PEPTIDE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; GERMANY; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; HYPERTENSION; INFLAMMATION; INTRAPERITONEAL FAT; LIPID ANALYSIS; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; OBESITY; POPULATION RESEARCH; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SEX DIFFERENCE; SOCIAL STATUS; SUBCUTANEOUS FAT; WAIST CIRCUMFERENCE; BLOOD; BLOOD PRESSURE; INTRA-ABDOMINAL FAT; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED;

ADULT; AGED; BLOOD PRESSURE; C-REACTIVE PROTEIN; CHEMOKINES; CYTOKINES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRA-ABDOMINAL FAT; LIPIDS; MALE; METABOLIC SYNDROME; MIDDLE AGED; SUBCUTANEOUS FAT; WAIST CIRCUMFERENCE;

EID: 85010424667     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.21735     Document Type: Article

References (40)

1. Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 2014;15:6184-6223.
2. Nagpal S, Patel S, Jacobe H, et al. Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin. J Invest Dermatol 1997;109:91-95.
3. Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003;198:977-985.
4. Rourke J, Dranse H, Sinal C. Towards an integrative approach to understanding the role of chemerin in human health and disease. Obes Rev 2013;14:245-262.
5. Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007;148:4687-4694.
6. Goralski KB, McCarthy TC, Hanniman EA, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007;282:28175-28188.
7. Lehrke M, Becker A, Greif M, et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol 2009;161:339-344.
8. Chakaroun R, Raschpichler M, Kloting N, et al. Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity. Metabolism 2012;61:706-714.
9. Bozaoglu K, Segal D, Shields KA, et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab 2009;94:3085-3088.
10. Yang M, Yang G, Dong J, et al. Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension. J Investig Med 2010;58:883-886.
11. Stejskal D, Karpisek M, Hanulova Z, Svestak M. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population–a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008;152:217-221.
12. Wang D, Yuan G, Wang X, et al. Plasma chemerin level in metabolic syndrome. Genet Mol Res 2013;12:5986-5991.
13. Völzke H, Alte D, Schmidt CO, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol 2011;40:294-307.
14. Carlson RV, Boyd KM, Webb DJ. The revision of the Declaration of Helsinki: past, present and future. Br J Clin Pharmacol 2004;57:695-713.
15. Müller HP, Raudies F, Unrath A, Neumann H, Ludolph AC, Kassubek J. Quantification of human body fat tissue percentage by MRI. NMR Biomed 2011;24:17-24.
16. National Cholesterol Education Program Expert Panel on Detection. Treatment of high blood cholesterol in, Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
17. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998;15:539-553.
18. Stone, C.J., C.-Y. Koo. Additive splines in statistics. In: Proceedings of the Statistical Computing Section ASA. Washington, DC: American Statistical Association (ASA); 1985. pp. 45-48.
19. Gu P, Jiang W, Lu B, Shi Z. Chemerin is associated with inflammatory markers and metabolic syndrome phenotypes in hypertension patients. Clin Exp Hypertens 2014;36:326-332.
20. Takahashi M, Inomata S, Okimura Y, et al. Decreased serum chemerin levels in male Japanese patients with type 2 diabetes: sex dimorphism. Endocr J 2013;60:37-44.
21. Alfadda AA, Sallam RM, Chishti MA, et al. Differential patterns of serum concentration and adipose tissue expression of chemerin in obesity: adipose depot specificity and gender dimorphism. Mol Cells 2012;33:591-596.
22. Klöting N, Blüher M. Adipocyte dysfunction, inflammation and metabolic syndrome. Rev Endocr Metab Disord 2014;15:277-287.
23. Svensson H, Odén B, Edén S, Lönn M. Adiponectin, chemerin, cytokines, and dipeptidyl peptidase 4 are released from human adipose tissue in a depot-dependent manner: an in vitro system including human serum albumin. BMC Endocr Disord 2014;14:7.
24. Kralisch S, Weise S, Sommer G, et al. Interleukin-1ß induces the novel adipokine chemerin in adipocytes in vitro. Regul Pept 2009;154:102-106.
25. Yamawaki H, Kameshima S, Usui T, Okada M, Hara Y. A novel adipocytokine, chemerin exerts anti-inflammatory roles in human vascular endothelial cells. Biochem Biophys Res Commun 2012;423:152-157.
26. Cash JL, Hart R, Russ A, et al. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J Exp Med 2008;205:767-775.
27. World Health Organization. Use of Glycated Haemoglobin (HbA1c) in Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation. WHO; 2011.
28. Yu S, Zhang Y, Li M, et al. Chemerin and apelin are positively correlated with inflammation in obese type 2 diabetic patients. Chin Med J 2012;125:3440-3444.
29. Takahashi M, Takahashi Y, Takahashi K, et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett 2008;582:573-578.
30. Takahashi M, Okimura Y, Iguchi G, et al. Chemerin regulates beta-cell function in mice. Sci Rep 2011;1:1-10.
31. Sell H, Laurencikiene J, Taube A, et al. Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes 2009;58:2731-2740.
32. Becker M, Rabe K, Lebherz C, et al. Expression of human chemerin induces insulin resistance in the skeletal muscle but does not affect weight, lipid levels, and atherosclerosis in LDL receptor knockout mice on high-fat diet. Diabetes 2010;59:2898-2903.
33. Yu QX, Zhang H, Xu WH, et al. Effect of irbesartan on chemerin in the renal tissues of diabetic rats. Kidney Blood Press Res 2015;40:467-477.
34. Borghi C, Dormi A, Veronesi M, Immordino V, Ambrosioni E. Use of lipid-lowering drugs and blood pressure control in patients with arterial hypertension. J Clin Hypertens (Greenwich) 2002;4:277-285.
35. Balfour PC Jr., Rodriguez CJ, Ferdinand KC. Blood pressure and cardiovascular effects of new and emerging antidiabetic agents. Curr Hypertens Rep 2014;16:1-9.
36. Aydın K, Canpolat Akın UŞ, et al. Chemerin is not associated with subclinical atherosclerosis markers in prediabetes and diabetes. Anatol J Cardiol 2016;16:749–755.
37. Nakamura K, Fuster JJ, Walsh K. Adipokines: a link between obesity and cardiovascular disease. J Cardiol 2014;63:250-259.
38. Kaur J, Adya R, Tan BK, Chen J, Randeva HS. Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis. Biochem Biophys Res Commun 2010;391:1762-1768.
39. Neves KB, Cat AND, Lopes RAM, et al. Chemerin regulates crosstalk between adipocytes and vascular cells through Nox. Hypertension 2015;66:657-666.
40. Rodriguez-Penas D, Feijoo-Bandin S, Garcia-Rua V, et al. The adipokine chemerin induces apoptosis in cardiomyocytes. Cell Physiol Biochem 2015;37:176-192.